We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 32.90 | 32.90 | 33.45 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -5.85M | -0.0194 | -16.98 | 99.08M |
Date | Subject | Author | Discuss |
---|---|---|---|
19/7/2023 07:46 | Glavey, your stock bashing is so second nature to you that you can't tolerate anything positive about this stock. It's obvious that whatever product Futura brought out, you would condemn it immediately, just like your mate LiarBOoth. Your sort are typical bb pariahs, you hate it when anyone does well from a stock. Do you think that wrapping up your nasty comments in fine words makes you sound like you know what you're talking about? It's obvious that you don't when you write off all the people and companies involved in bringing Eroxon to market as having less than half a brain, and branding Eroxon as snake oil when you have no proof. You're just another spamming stock basher. | petroc | |
19/7/2023 04:13 | [19396] Pet, I think you need to stop kidding yourself. Investing because you believed in the product is not supported by your action of selling out entirely early in the day on a news spike. That is the behaviour of a trader. Someone here, as you put it, (hopefully) to make money, a trait reflected in your general promotional behaviour and abject criticism of any other poster not supportive or providing alternative reasoning. Anyone with half a brain knows the product is 'snake oil' and equally knows that quality is enabling when it comes to trading the shares (if that's your bag). When you pretend otherwise and go about attacking posters who set out the reality of the case for the general record I'm afraid you leave your behaviour open to mockery and disapproval. | glavey | |
18/7/2023 21:31 | This advert in Brazilian Portuguese put up on LSE - it's an advert not a professional critique although it's done by an attractive Doctor - has had 400,000 views in 2 weeks. The advertorial makes the points: it's safe, doesn't work for every man but when it does works in as little time as 10 seconds for most men, doesn't have unpleasant side effects as Viagra does. PS And the price point is a lot lower than in the U.K. https://youtu.be/ITq | beanol | |
18/7/2023 21:09 | LBO1You are taking your post out of context from the article. The article basically says: the jury's out. They have all the authorisations but it's not cert to work. Nonetheless....Some of the comments on the article are hilarious. I liked this one:"Best article and best comments in WAPO today. Spit me coffee. ???"Let's face it: would the prestigious and highly US company have done this deal in such a reputationally sensitive area without having balanced all the risks and opportunities. I don't see the need for the angry bile in your posts or those from other people too. | beanol | |
18/7/2023 18:04 | No Fun with FUM | halfpenny | |
18/7/2023 17:13 | Lots of purchases reported after the close including 2 big ones.... 300,000 shares each | broomrigg | |
18/7/2023 16:42 | We always know when things are going the right way just from the number of posts from the bedwetters....its hilarious! BLUE day :-) | broomrigg | |
18/7/2023 15:46 | Go ahead. Short it. You know you want to ! | wheeze | |
18/7/2023 12:23 | Keeping away as the shares have gone limp!! | halfpenny | |
18/7/2023 12:19 | Keeping away as the shares have gone limp!! | halfpenny | |
18/7/2023 11:49 | Keep going, LiarBOoth and jonnybutler! I need to get back in here! | petroc | |
18/7/2023 09:11 | I can't disagree with halfpenny ;-) | broomrigg |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions